An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic

Rheumatology (Oxford). 2021 Feb 1;60(2):977-979. doi: 10.1093/rheumatology/keaa653.

Authors

Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹, Michael R Ehrenstein^{1

2}

Affiliations

¹ Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
² Department of Rheumatology, University College London, London, UK.

No abstract available

Publication types

Letter

MeSH terms

Abatacept / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Antirheumatic Agents / administration & dosage*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / physiopathology
COVID-19
Decision Making, Shared
Disease Progression
Drug Substitution*
Humans
Infusions, Intravenous
Injections, Subcutaneous
Patient Preference*
SARS-CoV-2
Self Administration
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Abatacept
tocilizumab